Krystle Vermes

FDA previously designated the once-daily intravenous antifungal as a Qualified Infectious Disease Product.

In a head-to-head study, aripiprazole treatment from H. Lundbeck A/S and Otsuka America Pharmaceutical Inc. showed superior effectiveness to Janssen's paliperidone palmitate treatment in adult patients with schizophrenia.

Astellas today announced that the FDA has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis, one of the most frequent invasive fungal infections detected in critically ill patients and a common cause of bloodstream infections.

The dangers of failing to change the clocks on insulin pumps in recognition of daylight saving time.

Three industry groups have collaborated to generate new approaches to care delivery through pharmacists that will lower medical costs and improve health outcomes.

Pfizer's serotonin and norepinephrine reuptake inhibitor, desvenlafaxine (Pristiq), has low potential for causing sexual dysfunction in patients with major depressive disorder.

Agave nectar and placebo may be more effective in treating a child's cough than "watchful waiting" with no treatment at all.

Women who develop gestational diabetes mellitus tend to have daughters who become obese later in childhood.

Tracking influenza vaccination among health care personnel through an automated system enhances their immunization compliance while reducing their administrative burden.

Current risk assessment strategies for reducing fractures related to osteoporosis among women fail to accurately predict who will experience major osteoporotic injuries.

Adults aged 50 years or older who feel comfortable about aging are more likely to seek preventive health care services.

The transdermal buprenorphine manufacturer has launched an awareness campaign to address specific knowledge gaps among pharmacists that pertain to opioids.

The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of Novartis' first-in-class secukinumab therapy for moderate-to-severe plaque psoriasis.

An estimated 6.9 million US adults aged 35 years and older had a combined 10.9 million self-reported smoking-attributable medical conditions in 2009.

The US Centers for Disease Control and Prevention uncovered clusters of high vaccination exemption at the local level, which leaves communities vulnerable to vaccine-preventable diseases.

Patients with moderate-to-severe psoriasis are more likely to have uncontrolled hypertension.

The disease burden of smoking remains immense despite widespread tobacco cessation efforts.

The vaccine that prevents illness and death from pneumococcal infection also combats severe antibiotic-resistant disease in young children.

Although many policymakers recommend universal screening for methicillin-resistant Staphylococcus aureus infection, individual hospitals may lack the funding to execute it.

Coaching patients with chronic obstructive pulmonary disease on relaxation techniques can improve their quality of life and even ease their symptoms.

In an effort to get the public more involved in medication optimization, Pfizer has introduced a new scratch card for patients.

The FDA has granted priority review to Roche's injectable ranibizumab (Lucentis) treatment for diabetic retinopathy.

Evolocumab is a fully human monoclonal antibody that cut low-density lipoprotein cholesterol levels by more than half.

Evolocumab cut low-density lipoprotein cholesterol levels by 60%, on average, in patients with heterozygous familial hypercholesterolemia

Tests that may help health care professionals diagnose influenza more quickly and accurately have received support from the US Department of Health and Human Services.

A multidisciplinary group of medical and nutrition experts hopes to shed light on misconceptions about vitamin and mineral supplementation.

Secukinumab improved peripheral joint disease, prevented joint damage, and produced clear or almost clear skin in a pair of pivotal Phase 3 trials.

Latanoprostene bunod (Vesneo) demonstrated noninferiority to timolol maleate (Timoptic 5%) in pivotal Phase 3 studies.

The FDA launched the "Know Your Source" program to help health care professionals spot counterfeit drugs and reduce the threat of illegal drug trading.

Influenza boosts the ability of pneumococci to cause middle ear and throat infections.